Profusa Updates Multiple Financing Agreements With Ascent Partners Fund

Profusa amended two financing agreements with Ascent Partners Fund to increase flexibility for near-term capital raising. The equity line floor price was adjusted, and the senior secured convertible note was updated to eliminate amortization and set mandatory prepayments. These changes aim to optimize liquidity and align financing terms ahead of a proposed reverse stock split.

Profusa Inc. Announces $100 Million Private Placement of Common Stock

Profusa Inc. has amended its Securities Purchase Agreement with Ascent Partners Fund LLC to issue and sell up to $100 million of its common stock in a private placement. Shares may be issued at a floor price of $0.111 per share for up to 13,650,000 shares, reverting to $0.14 per share after a reverse stock split expected in January 2026. The agreement is subject to conditions and limitations.

12 Health Care Stocks Moving In Monday's Intraday Session

On Monday, several healthcare stocks experienced significant intraday movements. Notable gainers included Jyong Biotech, up 89.6% to $6.02, and Equillium, up 29.56% to $1.49. Among the losers, EUDA Health Holdings fell 56.9% to $1.23, and Profusa dropped 27.24% to $0.09. The article was generated by Benzinga's automated content engine and reviewed by an editor.

Profusa Inc. Announces Date for Upcoming Special Stockholders Meeting

Profusa Inc. will hold a special virtual stockholders meeting via teleconference on (●), 2026, to address matters described in the meeting materials. The original content was published via EDGAR by the U.S. SEC on December 22, 2025.

Profusa shares are trading higher after the company reported late-breaking data showing its Lumee oxygen monitoring system met primary endpoints in a peripheral artery disease study.